<DOC>
	<DOCNO>NCT00525148</DOCNO>
	<brief_summary>The primary objective open-label , single arm Phase II trial explore efficacy BIBW 2992 define objective response rate ( CR , PR ) determine RECIST criterion patient advance NSCLC Stage IIIB IV whose tumor harbor activate mutation within exon 18 exon 21 EGFR receptor . Patients progress relapse one prior cytotoxic chemotherapy regimen well chemotherapy na誰ve patient ( stage 2 ) allow enter trial .</brief_summary>
	<brief_title>LUX Lung 2 Phase II Single Arm BIBW 2992 `` Afatinib '' NSCLC With EGFR Activating Mutations</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients pathologically confirm diagnosis NSCLC Stage IIIB ( pleural effusion ) adenocarcinoma Stage IV adenocarcinoma . 2 . Presence activate mutation ( ) exon 18 exon 21 EGFRreceptor confirm direct DNA sequence NSCLC tumor tissue . 3 . Progressive disease follow first line cytotoxic chemotherapy regimen recurrent disease prior neoadjuvant adjuvant chemotherapy . Patients receive firstline cytotoxic chemotherapy enrol stage 2 trial , criterion enter stage 2 meet . 4 . Patients least one tumor lesion accurately measure compute tomography ( CT ) magnetic resonance imaging ( MRI ) least one dimension long diameter record 20 mm use conventional technique 10 mm spiral CT scan . 5 . Male female patient age 18 year . 6 . Life expectancy least three ( 3 ) month . 7 . Written inform consent consistent ICHGCP guideline . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 , 1 2 . Exclusion criterion : 1 . More one ( 1 ) prior cytotoxic chemotherapy treatment regimen relapse metastatic NSCLC . 2 . Chemo , hormone ( Megace速 ) immunotherapy within past 4 week within less four halflives previous drug prior treatment trial drug and/or persistence toxicity prior anticancer therapy deem clinically relevant . 3 . Previous treatment erlotinib ( Tarceva速 ) , gefitinib ( Iressa速 ) EGFR inhibit small molecule antibody . 4 . Brain metastasis , symptomatic ; patient treat , asymptomatic brain metastasis eligible stable brain disease least four ( 4 ) week without requirement steroid antiepileptic therapy . 5 . Significant recent acute gastrointestinal disorder diarrhea major symptom e.g. , Crohns disease , malabsorption , CTCAE Grade &gt; 2 diarrhea etiology baseline . 6 . Patients lifethreatening illness organ system dysfunction , opinion investigator , would either compromise patient safety interfere evaluation safety test drug . 7 . Other malignancy diagnose within past five ( 5 ) year ( nonmelanomatous skin cancer situ cervical cancer ) . 8 . Radiotherapy within past 2 week prior treatment trial drug . 9 . Patients serious active infection ( i.e. , require IV antibiotic , antifungal , antiviral agent ) . 10 . Patients know HIV , active hepatitis B active hepatitis C. 11 . Known suspected active drug alcohol abuse . 12 . Women childbearing potential men able father child unwilling use medically acceptable method contraception trial . 13 . Pregnancy breast feed . 14 . Patient unable comply protocol . 15 . History clinically significant uncontrolled cardiac disease , include congestive heart failure , angina , myocardial infarction , arrhythmia , include New York Heart Association ( NYHA ) functional classification 3 . 16 . Cardiac leave ventricular function rest ejection fraction le 50 % measure multigated blood pool image heart ( MUGA scan ) echocardiogram . 17 . QTc interval great 0.47 second . 18 . Prior treatment anthracyclines cumulative dose doxorubicin ( equivalent ) great 400 mg/m2 . 19 . Absolute neutrophil count ( ANC ) less 1500/mm3 . 20 . Platelet count less 100 000 /mm3 . 21 . Bilirubin great 1.5 mg / dl ( great 26 micromol / L , SI unit equivalent ) . 22 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great three time upper limit normal ( related liver metastasis great five time upper limit normal ) . 23 . Serum creatinine great 1.5 time upper normal limit calculated/measured creatinine clearance equal le 45 ml / min . 24 . Patients know preexist interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>